Top

Published in:

19-12-2023 | Diabetic Retinopathy | Review Article

Biomarkers and signaling pathways of diabetic nephropathy and peripheral neuropathy: possible therapeutic intervention of rutin and quercetin

Authors: Tamsheel Fatima Roohi, Seema Mehdi, Sadaf Aarfi, K. L. Krishna, Suman Pathak, Seikh Mohammad Suhail, Syed Faizan

Published in: Diabetology International | Issue 2/2024

Abstract

Diabetic nephropathy and peripheral neuropathy are the two main complications of chronic diabetes that contribute to high morbidity and mortality. These conditions are characterized by the dysregulation of multiple molecular signaling pathways and the presence of specific biomarkers such as inflammatory cytokines, indicators of oxidative stress, and components of the renin–angiotensin system. In this review, we systematically collected and collated the relevant information from MEDLINE, EMBASE, ELSEVIER, PUBMED, GOOGLE, WEB OF SCIENCE, and SCOPUS databases. This review was conceived with primary objective of revealing the functions of these biomarkers and signaling pathways in the initiation and progression of diabetic nephropathy and peripheral neuropathy. We also highlighted the potential therapeutic effectiveness of rutin and quercetin, two plant-derived flavonoids known for their antioxidant and anti-inflammatory properties. The findings of our study demonstrated that both flavonoids can regulate important disease-promoting systems, such as inflammation, oxidative stress, and dysregulation of the renin–angiotensin system. Importantly, rutin and quercetin have shown protective benefits against nephropathy and neuropathy in diabetic animal models, suggesting them as potential therapeutic agents. These findings provide a solid foundation for further comprehensive investigations and clinical trials to evaluate the potential of rutin and quercetin in the management of diabetic nephropathy and peripheral neuropathy. This may contribute to the development of more efficient and comprehensive treatment approaches for diabetes-associated complications.

World Health Organisation. Diabetes. 2023. https://www.who.int/news-room/fact-sheets/detail/diabetes.

Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2018;88:1254–64.CrossRef

Aronson D. Hyperglycemia and the pathobiology of diabetic complications. In: Advances in cardiology, vol. 45. KARGER; 2018. p. 1–16. https://doi.org/10.1159/000115118.CrossRef

Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2020;26(2):77–82. https://doi.org/10.2337/diaclin.26.2.77.CrossRef

Fineberg D, Jandeleit-Dahm KAM, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2018;9(12):713–23. https://doi.org/10.1038/nrendo.2013.184.CrossRef

Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol. 2019;9(11):2157–69.CrossRef

Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2019;25(6):971–1010. https://doi.org/10.1210/er.2003-0018.CrossRef

Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev. 2019;5(1):41. https://doi.org/10.1038/s41572-019-0092-1.CrossRef

Yang H, Sloan G, Ye Y, Wang S, Duan B, Tesfaye S, Gao L. New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection, and precision medicine. Front Endocrinol. 2020. https://doi.org/10.3389/fendo.2019.00929.CrossRef

10.

World Health Organisation. WHO supports scientifically-proven traditional medicine. World Health Organisation. Africa Region. 2020. https://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine.

11.

Altemimi A, Lakhssassi N, Baharlouei A, Watson DG, Lightfoot DA. Phytochemicals: extraction, isolation, and identification of bioactive compounds from plant extracts. Plants. 2017. https://doi.org/10.3390/plants6040042.CrossRefPubMedPubMedCentral

12.

Parveen A, Jin M, Kim SY. Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy. Phytomedicine. 2018;39:146–59. https://doi.org/10.1016/j.phymed.2017.12.018.CrossRefPubMed

13.

Khan MA, Kassianos A, Hoy W, Alam K, Healy H, Gobe G. Promoting plant-based therapies for chronic kidney disease. J Evid-Based Integr Med. 2022;27:2515690X2210796. https://doi.org/10.1177/2515690X221079688.CrossRef

14.

Kumar A, Konar A, Garg S, Kaul SC, Wadhwa R. Experimental evidence and mechanism of action of some popular neuro-nutraceutical herbs. Neurochem Int. 2021;149: 105124. https://doi.org/10.1016/j.neuint.2021.105124.CrossRefPubMed

15.

Tiwari R, Siddiqui MH, Mahmood T, Bagga P, Ahsan F, Shamim A. Herbal remedies: a boon for diabetic neuropathy. J Diet Suppl. 2019;16(4):470–90. https://doi.org/10.1080/19390211.2018.1441203.CrossRefPubMed

16.

Tran N, Pham B, Le L. Bioactive compounds in antidiabetic plants: from herbal medicine to modern drug discovery. Biology. 2020. https://doi.org/10.3390/biology9090252.CrossRefPubMedPubMedCentral

17.

Wali JA, Masters SL, Thomas HE. Linking metabolic abnormalities to apoptotic pathways in beta cells in type 2 diabetes. Cells. 2013;2(2):266–83. https://doi.org/10.3390/cells2020266.CrossRefPubMedPubMedCentral

18.

Tamru K, Aga F, Berhanie E, Aynalem YA, Shiferaw WS. Incidence of diabetic nephropathy in patients with type 2 diabetes mellitus at a tertiary healthcare setting in Ethiopia. Diabetes Metab Syndr. 2020;14(5):1077–83. https://doi.org/10.1016/j.dsx.2020.06.028.CrossRefPubMed

19.

Grenfell A, Bewick M, Parsons V, Snowden S, Taube D, Watkins PJ. Non-insulin-dependent diabetes and renal replacement therapy. Diabet Med. 1988;5(2):172–6. https://doi.org/10.1111/j.1464-5491.1988.tb00966.x.CrossRefPubMed

20.

Martin C, Albers J, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:31–8. https://doi.org/10.2337/dc13-2114.CrossRefPubMed

21.

Das S, Behera J, Rojaramani Y, Mohanty R. Effects of resveratrol on oxidative stress in high fat diet/streptozocin induced diabetic wistar albino rats. Int J Basic Clin Pharmacol. 2019;8:482. https://doi.org/10.18203/2319-2003.ijbcp20190651.CrossRef

22.

Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan C-W, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Murray CJL. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90. https://doi.org/10.1016/S0140-6736(18)31694-5.CrossRefPubMedPubMedCentral

23.

Rico-Fontalvo J, Aroca-Martínez G, Daza-Arnedo R, Cabrales J, Rodríguez-Yanez T, Cardona-Blanco M, Montejo-Hernández J, Rodelo Barrios D, Patiño-Patiño J, Osorio Rodríguez E. Novel biomarkers of diabetic kidney disease. Biomolecules. 2023. https://doi.org/10.3390/biom13040633.CrossRefPubMedPubMedCentral

24.

Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–95.CrossRefPubMed

25.

Van Buren PN, Toto R. Current update in the management of diabetic nephropathy. Curr Diabetes Rev. 2013;9(1):62–77. https://doi.org/10.2174/157339913804143207.CrossRefPubMed

26.

Hussain S, Chand Jamali M, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: an overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Glob Health. 2021;9:2–6. https://doi.org/10.1016/j.cegh.2020.05.016.CrossRef

27.

Liao D, Ma L, Liu J, Fu P. Cigarette smoking as a risk factor for diabetic nephropathy: a systematic review and meta-analysis of prospective cohort studies. PLoS ONE. 2019;14: e0210213. https://doi.org/10.1371/journal.pone.0210213.CrossRefPubMedPubMedCentral

28.

Vimalkumar VK, Anand Moses CR, Padmanaban S. Prevalence & risk factors of nephropathy in type 2 diabetic patients. Int J Collab Res Internal Med Public Health. 2011;3(8):598.

29.

Amico JA, Klein I. Diabetic management in patients with renal failure. Diabetes Care. 1981;4(3):430–4. https://doi.org/10.2337/diacare.4.3.430.CrossRefPubMed

30.

Gurley SB, Ghosh S, Johnson SA, Azushima K, Sakban RB, George SE, Maeda M, Meyer TW, Coffman TM. Inflammation and immunity pathways regulate genetic susceptibility to diabetic nephropathy. Diabetes. 2018;67(10):2096–106. https://doi.org/10.2337/db17-1323.CrossRefPubMedPubMedCentral

31.

Seyer-Hansen K. Renal hypertrophy in experimental diabetes: a comparison to compensatory hypertrophy. Diabetologia. 1978;14(5):325–8. https://doi.org/10.1007/BF01223024.CrossRefPubMed

32.

Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456–80. https://doi.org/10.4239/wjd.v6.i3.456.CrossRefPubMedPubMedCentral

33.

Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361.CrossRefPubMed

34.

Tan ALY, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Diabetic Nephrop. 2007;27(2):130–43. https://doi.org/10.1016/j.semnephrol.2007.01.006.CrossRef

35.

Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharmaceutica Sinica B. 2021;11(9):2749–67. https://doi.org/10.1016/j.apsb.2020.12.020.CrossRefPubMedPubMedCentral

36.

Hovind P, Tarnow L, Rossing P, Graae M, Torp I, Binder C, Parving H-H. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328(7448):1105. https://doi.org/10.1136/bmj.38070.450891.FE.CrossRefPubMedPubMedCentral

37.

Zimmerman SW, Sollinger H, Wakeen M, Armbrust M, Cole D, Kearney ME, Kalker A. Renal replacement therapy in diabetic nephropathy. Adv Ren Replace Ther. 1994;1(1):66–74. https://doi.org/10.1016/S1073-4449(12)80023-9.CrossRefPubMed

38.

Natarajan R. Epigenetic mechanisms in diabetic vascular complications and metabolic memory: the 2020 Edwin Bierman Award Lecture. Diabetes. 2021;70(2):328–37. https://doi.org/10.2337/dbi20-0030.CrossRefPubMedPubMedCentral

39.

Ni W-J, Tang L-Q, Wei W. Research progress in signaling pathway in diabetic nephropathy. Diabetes Metab Res Rev. 2015;31(3):221–33. https://doi.org/10.1002/dmrr.2568.CrossRefPubMed

40.

Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, Nishikawa M, Inada M, Fujimura Y, Ikeda Y, Fukuhara S. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost. 1998;80:388–92.CrossRefPubMed

41.

Gupta A, Singh K, Fatima S, Ambreen S, Zimmermann S, Younis R, Krishnan S, Rana R, Gadi I, Schwab C, Biemann R, Shahzad K, Rani V, Ali S, Mertens PR, Kohli S, Isermann B. Neutrophil extracellular traps promote NLRP3 inflammasome activation and glomerular endothelial dysfunction in diabetic kidney disease. Nutrients. 2022. https://doi.org/10.3390/nu14142965.CrossRefPubMedPubMedCentral

42.

Satirapoj B, Nast C, Adler S. Novel insights into the relationship between glomerular pathlogy and progressive kidney disease. Adv Chron Kidney Dis. 2012;19:93–100. https://doi.org/10.1053/j.ackd.2011.12.001.CrossRef

43.

Lee C, An D, Park J. Hyperglycemic memory in metabolism and cancer. Horm Mol Biol Clin Investig. 2016;26(2):77–85. https://doi.org/10.1515/hmbci-2016-0022.CrossRefPubMed

44.

Anderson S, Brenner BM. Pathogenesis of diabetic glomerulopathy: the role of glomerular hyperfiltration. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Springer US; 1988. p. 139–46.CrossRef

45.

Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract. 2008;82:S75–9. https://doi.org/10.1016/j.diabres.2008.09.042.CrossRefPubMed

46.

Wolffenbuttel BHR, Boulanger CM, Crijns FRL, Huijberts MSP, Poitevin P, Swennen GNM, Vasan S, Egan JJ, Ulrich P, Cerami A, Lévy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci. 1998;95(8):4630–4. https://doi.org/10.1073/pnas.95.8.4630.CrossRefPubMedPubMedCentral

47.

Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin Nephrol. 2003;23(2):194–9. https://doi.org/10.1053/snep.2003.50017.CrossRefPubMed

48.

Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, Araki E. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes. 2003;52(10):2570–7. https://doi.org/10.2337/diabetes.52.10.2570.CrossRefPubMed

49.

Xue R, Gui D, Zheng L, Zhai R, Wang F, Wang N. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J Diabetes Res. 2017;2017:1839809. https://doi.org/10.1155/2017/1839809.CrossRefPubMedPubMedCentral

50.

Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44(11):1957–72. https://doi.org/10.1007/s001250100000.CrossRefPubMed

51.

Mauer M, Zinman B, Gardiner R, Suisse S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler M, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51. https://doi.org/10.1056/NEJMoa0808400.CrossRefPubMedPubMedCentral

52.

Buraczynska M, Ksiazek K, Wacinski P, Zaluska W. Interleukin-1β gene (IL1B) polymorphism and risk of developing diabetic nephropathy. Immunol Invest. 2019;48(6):577–84. https://doi.org/10.1080/08820139.2019.1595642.CrossRefPubMed

53.

Cui Z, Lu X, Xiao K, Chen Y, Li H. Association of interleukin-6 -174G/C polymorphism with the risk of diabetic nephropathy in type 2 diabetes: a meta-analysis. Curr Med Sci. 2019;39(2):250–8. https://doi.org/10.1007/s11596-019-2027-1.CrossRefPubMed

54.

Cortvrindt C, Speeckaert R, Moerman A, Delanghe J, Speeckaert M. The role of interleukin-17A in the pathogenesis of kidney diseases. Pathology. 2017. https://doi.org/10.1016/j.pathol.2017.01.003.CrossRefPubMed

55.

Fujita T, Ogihara N, Kamura Y, Satomura A, Fuke Y, Shimizu C, Wada Y, Matsumoto K. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 2012;49(2):111–7. https://doi.org/10.1007/s00592-010-0178-4.CrossRefPubMed

56.

Lemos DR, McMurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, Wang G, Morizane R, Bonventre JV, Duffield JS. Interleukin-1β activates a MYC-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J Am Soc Nephrol. 2018;29(6):1690.CrossRefPubMedPubMedCentral

57.

Liu S, Chen J, Li Y. Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy. J Diabetes Investig. 2018;9(5):1182–8. https://doi.org/10.1111/jdi.12828.CrossRefPubMedPubMedCentral

58.

Stahel M, Becker M, Graf N, Michels S. SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: a prospective open-label study using canakinumab. Retina. 2016;36(2):385–91.CrossRefPubMedPubMedCentral

59.

Yaribeygi H, Atkin SL, Sahebkar A. Interleukin-18 and diabetic nephropathy: a review. J Cell Physiol. 2019;234(5):5674–82. https://doi.org/10.1002/jcp.27427.CrossRefPubMed

60.

Foundation NK. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2):S12–S154. https://doi.org/10.1053/j.ajkd.2006.12.005

61.

Fontalvo JER. Clinical practice guidelines for diabetic kidney disease. Revista Colombiana e Nefrología. 2021;8: e561.

62.

Peña MJ, Mischak H, Heerspink HJL. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia. 2016;59(9):1819–31. https://doi.org/10.1007/s00125-016-4001-9.CrossRefPubMedPubMedCentral

63.

Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61(5):996–1011. https://doi.org/10.1007/s00125-018-4567-5.CrossRefPubMedPubMedCentral

64.

Looker HC, Mauer M, Nelson RG. Role of kidney biopsies for biomarker discovery in diabetic kidney disease. Adv Chron Kidney Dis. 2018;25:192–201.CrossRef

65.

Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK. Prospective diabetes study 74. Diabetes. 2006;55(6):1832–9. https://doi.org/10.2337/db05-1620.CrossRefPubMed

66.

Branten AJW, Vervoort G, Wetzels JFM. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005;20(4):707–11. https://doi.org/10.1093/ndt/gfh719.CrossRefPubMed

67.

Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. https://doi.org/10.1155/2021/1497449.CrossRefPubMedPubMedCentral

68.

Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy. J Diabetes Res. 2018;2018:2852398. https://doi.org/10.1155/2018/2852398.CrossRefPubMedPubMedCentral

69.

Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract. 2014;33(3):121–31. https://doi.org/10.1016/j.krcp.2014.08.001.CrossRefPubMedPubMedCentral

70.

Satirapoj B, Adler SG. Prevalence and management of diabetic nephropathy in western countries. Kidney Dis. 2015;1(1):61–70. https://doi.org/10.1159/000382028.CrossRef

71.

Devarajan P. The use of targeted biomarkers for chronic kidney disease. Proteom Anal Study Chron Kidney Dis. 2010;17(6):469–79. https://doi.org/10.1053/j.ackd.2010.09.002.CrossRef

72.

Cheng C-W, Chang C-C, Chen H-W, Lin C-Y, Chen J-S. Serum ApoA4 levels predicted the progression of renal impairment in T2DM. Eur J Clin Invest. 2018;48(6): e12937. https://doi.org/10.1111/eci.12937.CrossRefPubMed

73.

Pertseva N, Borisova I. TGF-β1 and VCAM-1 serum concentrations as diagnostic biomarkers of diabetic kidney disease progression. Rom J Diabetes Nutr Metab. 2019;2:169–75.

74.

Cho E-H, Kim M-R, Kim H-J, Lee D-Y, Kim P-K, Choi KM, Ryu O-H, Kim C-W. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. PROTEOMICS Clin Appl. 2007;1(4):352–61. https://doi.org/10.1002/prca.200600608.CrossRefPubMed

75.

Lee C-H, Lam KSL. Biomarkers of progression in diabetic nephropathy: the past, present and future. J Diabetes Investig. 2015;6(3):247–9. https://doi.org/10.1111/jdi.12329.CrossRefPubMedPubMedCentral

76.

Jayachandran I, Sundararajan S, Paramasivam P, Venkatesan B, Subramanian SC, Balasubramanyam M, Mohan V, Manickam N. Association of circulatory asymmetric dimethylarginine (ADMA) with diabetic nephropathy in Asian Indians and its causative role in renal cell injury. Clin Biochem. 2017;50(15):835–42. https://doi.org/10.1016/j.clinbiochem.2017.05.007.CrossRefPubMed

77.

Kamel MF, Nassar M, Elbendary A, Mohamed AGA, Abdullah MG, Gomaa HRA, Awad EMI, Mahmoud HH, Elfiki MA, Abdalla NH, Abd Elkareem RM, Soliman AS, Elmessiery RM. The potential use of urinary transferrin, urinary adiponectin, urinary retinol binding protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: a case-control study. Diabetes Metab Syndr. 2022;16(4): 102473. https://doi.org/10.1016/j.dsx.2022.102473.CrossRefPubMed

78.

Alnaggar ARLR, Sayed M, El-deena KE, Gomaa M, Hamed Y. Evaluation of serum adiponectin levels in diabetic nephropathy. Diabetes Metab Syndr. 2019;13(1):128–31. https://doi.org/10.1016/j.dsx.2018.04.035.CrossRefPubMed

79.

Khan NU, Lin J, Liu X, Li H, Lu W, Zhong Z, Zhang H, Waqas M, Shen L. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochimica et Biophysica Acta (BBA) Proteins and Proteomics. 2020;1868(10):140475. https://doi.org/10.1016/j.bbapap.2020.140475.CrossRefPubMed

80.

Tan KCB, Cheung C-L, Lee ACH, Lam JKY, Wong Y, Shiu SWM. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus. Diabetologia. 2018;61(5):1212–9. https://doi.org/10.1007/s00125-018-4552-z.CrossRefPubMed

81.

Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, Carrero JJ, Riserus U, Ingelsson E, Fall T, Ärnlöv J. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Upsala J Med Sci. 2020;125(1):37–43. https://doi.org/10.1080/03009734.2019.1696430.CrossRefPubMed

82.

Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, de Boer IH, Essioux L, Formentini I, Gadegbeku CA, Gipson D, Hawkins J, Himmelfarb J, Kestenbaum B, Kretzler M, Magnone MC, Perumal K, Steigerwalt S, Bansal N. Growth differentiation factor–15 and risk of CKD progression. J Am Soc Nephrol. 2017;28(7):2233–40.CrossRefPubMedPubMedCentral

83.

Hanefeld M, Appelt D, Engelmann K, Sandner D, Bornstein S, Ganz X, Henkel E, Haase R, Birkenfeld A. Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy. Horm Metab Res. 2016;48:620–620. https://doi.org/10.1055/s-0036-1585504.CrossRefPubMed

84.

El-Ashmawy NE, El-Zamarany EA, Khedr NF, Abd El-Fattah AI, Eltoukhy SA. Kidney injury molecule-1 (Kim-1): an early biomarker for nephropathy in type II diabetic patients. Int J Diabetes Dev Ctries. 2015;35(3):431–8. https://doi.org/10.1007/s13410-015-0403-3.CrossRef

85.

Rysz J, Gluba-Brzózka A, Franczyk B, Jabłonowski Z, Ciałkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18081702.CrossRefPubMedPubMedCentral

86.

Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, Bell M, Forni L, Guzzi L, Joannidis M, Kane-Gill SL, Legrand M, Mehta R, Murray PT, Pickkers P, Plebani M, Prowle J, Ricci Z, Rimmelé T, Ronco C. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3(10): e2019209. https://doi.org/10.1001/jamanetworkopen.2020.19209.CrossRefPubMed

87.

Pop-Busui R, Boulton AJM, Sosenko JM. CHAPTER 23 PERIPHERAL AND AUTONOMIC NEUROPATHY IN DIABETES. 2017

88.

Pop-Busui R, Ang L, Boulton AJM, Feldman EL, Marcus RL, Mizokami-Stout K, Singleton JR, Ziegler D. Diagnosis and treatment of painful diabetic peripheral neuropathy. Compendia. 2022;2022(1):1–32. https://doi.org/10.2337/db2022-01.CrossRef

89.

Mather KJ, Bebu I, Baker C, Cohen RM, Crandall JP, DeSouza C, Green JB, Kirkman MS, Krause-Steinrauf H, Larkin M, Pettus J, Seaquist ER, Soliman EZ, Schroeder EB, Wexler DJ, Pop-Busui R. Prevalence of microvascular and macrovascular disease in the glycemia reduction approaches in diabetes—a comparative effectiveness (GRADE) study cohort. Diabetes Res Clin Pract. 2020;165: 108235. https://doi.org/10.1016/j.diabres.2020.108235.CrossRefPubMedPubMedCentral

90.

Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R Jr, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH, Pop-Busui R, Saydah S, Hamman RF, Pihoker C, for the SEARCH for Diabetes in Youth Research Group. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317(8):825–35. https://doi.org/10.1001/jama.2017.0686.CrossRefPubMedPubMedCentral

91.

Braffett BH, Gubitosi-Klug RA, Albers JW, Feldman EL, Martin CL, White NH, Orchard TJ, Lopes-Virella M, Lachin JM, Pop-Busui R, DCCT/EDIC Research Group. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes. 2020;69(5):1000–10. https://doi.org/10.2337/db19-1046.CrossRefPubMedPubMedCentral

92.

Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. https://doi.org/10.1007/s11910-014-0473-5.CrossRefPubMedPubMedCentral

93.

Smith S, Normahani P, Lane T, Hohenschurz-Schmidt D, Oliver N, Davies AH. Pathogenesis of distal symmetrical polyneuropathy in diabetes. Life. 2022. https://doi.org/10.3390/life12071074.CrossRefPubMedPubMedCentral

94.

Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006. https://doi.org/10.1136/pgmj.2005.036137.CrossRefPubMedPubMedCentral

95.

Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521–34. https://doi.org/10.1016/S1474-4422(12)70065-0.CrossRefPubMedPubMedCentral

96.

Gerstein HC, Miller ME, Byington RP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed

97.

Callaghan BC, Little AA, Feldman EL, Hughes R. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD007543.pub2.CrossRefPubMed

98.

ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. https://doi.org/10.1016/S0140-6736(10)60576-4.CrossRef

99.

Bondar A, Cosmin Mihai V, Sabau M, Stoica RA, Pantea Stoian A. Diabetic neuropathy: a narrative review of risk factors, classification, screening and current pathogenic treatment options. Exp Therap Med. 2021. https://doi.org/10.3892/etm.2021.10122.CrossRef

100.

Ardeleanu V, Toma A, Pafili P, Motofei I, Diaconu C, Rizzo M, Pantea Stoian A. Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina. 2020;56:25. https://doi.org/10.3390/medicina56010025.CrossRefPubMedPubMedCentral

101.

Gregory JA, Jolivalt CG, Goor JB, Mizisin AP, Calcutt NA. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol. 2012;124:561–73.CrossRefPubMed

102.

Elliott J, Tesfaye S, Chaturvedi N, Gandhi R, Stevens L, Emery C, Fuller J. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk Factors. Diabetes Care. 2009;32:1896–900. https://doi.org/10.2337/dc09-0554.CrossRefPubMedPubMedCentral

103.

Schlesinger S, Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, Bönhof GJ, Koenig W, Heier M, Peters A, Meisinger C, Roden M, Thorand B, Ziegler D. General and abdominal obesity and incident distal sensorimotor polyneuropathy: insights into inflammatory biomarkers as potential mediators in the KORA F4/FF4 cohort. Diabetes Care. 2018;42(2):240–7. https://doi.org/10.2337/dc18-1842.CrossRefPubMed

104.

Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015;314(20):2172–81. https://doi.org/10.1001/jama.2015.13611.CrossRefPubMedPubMedCentral

105.

Boulton AJM. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes Neurodiab. Diabetes Metab. 1998;24(Suppl 3):55–65.PubMed

106.

Dyck P, Albers J, Andersen H, Arezzo J, Biessels G, Bril V, Feldman E, Litchy W, O’Brien P, Russell J, Tesfaye S. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27:620–8. https://doi.org/10.1002/dmrr.1226.CrossRefPubMed

107.

Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R, Malik R, Maser R, Sosenko J. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62. https://doi.org/10.2337/diacare.28.4.956.CrossRefPubMed

108.

Tesfaye SH, Boulton AJM, Dyck PJB, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik AI, dos Bernardi LS, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.CrossRefPubMedPubMedCentral

109.

Boulton AJM, Valensi P, Tesfaye SH. International neuropathy workshop of 2009: introduction to the final reports. Diabetes/Metab Res Rev. 2011;27:617–9.CrossRefPubMed

110.

Zakin E, Abrams R, Simpson D. Diabetic neuropathy. Semin Neurol. 2019;39:560–9. https://doi.org/10.1055/s-0039-1688978.CrossRefPubMed

111.

Freeman R. Chapter 6—Diabetic autonomic neuropathy. In: Zochodne DW, Malik RA, editors. Handbook of clinical neurology, vol. 126. Cham: Elsevier; 2014. p. 63–79.

112.

Normahani P, Shalhoub J. Diabetic foot disease. Surg Infect (Larchmt). 2022;40(1):53–61. https://doi.org/10.1016/j.mpsur.2021.11.007.CrossRef

113.

Harris MI, Eastman R, Cowie CC. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care. 1993;16:1446–52.CrossRefPubMed

114.

Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care. 2011;34(10):2220–4. https://doi.org/10.2337/dc11-1108.CrossRefPubMedPubMedCentral

115.

Herman W, Pop-Busui R, Braffett B, Martin C, Cleary P, Albers J, Feldman E. Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabetic Med J Brit Diabetic Assoc. 2012;29:937. https://doi.org/10.1111/j.1464-5491.2012.03644.x.CrossRef

116.

Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29(2):340.CrossRefPubMed

117.

Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.671257.CrossRef

118.

Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: register initiative “diabetes and nerves.” Endocr Metab Sci. 2020;1(1): 100053. https://doi.org/10.1016/j.endmts.2020.100053.CrossRef

119.

Vileikyte L, Peyrot M, Bundy C, Rubin RR, Leventhal H, Mora P, Shaw JE, Baker P, Boulton AJM. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care. 2003;26(9):2549–55. https://doi.org/10.2337/diacare.26.9.2549.CrossRefPubMed

120.

Davoudi M, Rezaei P, Rajaeiramsheh F, Ahmadi SM, Taheri AA. Predicting the quality of life based on pain dimensions and psychiatric symptoms in patients with Painful diabetic neuropathy: a cross-sectional prevalence study in Iranian patients. Health Qual Life Outcomes. 2021;19(1):49. https://doi.org/10.1186/s12955-021-01697-w.CrossRefPubMedPubMedCentral

121.

Xavier A, Foss M, Marques W, Santos C, Onofre P, Pace A. Cultural adaptation and validation of the neuropathy—and foot ulcer—specific quality of life instrument (NeuroQol) for Brazilian Portuguese—phase 1. Rev Lat Am Enfermagem. 2011;19:1352–61. https://doi.org/10.1590/S0104-11692011000600011.CrossRefPubMed

122.

Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, Waterman C, Ulbrecht JS, Cavanagh PR, Boulton AJM. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009;52(7):1265–73. https://doi.org/10.1007/s00125-009-1363-2.CrossRefPubMed

123.

Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A Practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.CrossRefPubMed

124.

Yu Y. Gold standard for diagnosis of DPN. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.719356.CrossRef

125.

Abdissa D, Sorsa R, Gerbi A, Hamba N, Banjaw Z. Magnitude and associated factors of peripheral neuropathy among diabetes patients attending Jimma University Medical Center Southwest Ethiopia. Heliyon. 2021;7(11): e08460. https://doi.org/10.1016/j.heliyon.2021.e08460.CrossRefPubMedPubMedCentral

126.

Viswanathan V, Ahmed Khan B, Nachimuthu S, Kumpatla S. Precision of Michigan neuropathy screening instrument (MNSI) tool for the diagnosis of diabetic peripheral neuropathy among people with type 2 diabetes—a study from South India. Int J Lower Extrem Wounds. 2023. https://doi.org/10.1177/15347346231163209.CrossRef

127.

Vinik E, Hayes R, Oglesby A, Bastyr E III, Barlow P, Ford-Molvik S, Vinik A. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497–508. https://doi.org/10.1089/dia.2005.7.497.CrossRefPubMed

128.

Vinik E, Vinik A, Paulson J, Merkies I, Packman J, Grogan D, Coelho T. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014. https://doi.org/10.1111/jns5.12059.CrossRefPubMedPubMedCentral

129.

Vinik EJ, Paulson JF, Ford-Molvik SL, Vinik AI. German-Translated Norfolk Quality of Life (QOL-DN) identifies the same factors as the english version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol. 2008;2(6):1075–86. https://doi.org/10.1177/193229680800200616.CrossRefPubMedPubMedCentral

130.

Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. (n.d.). Diabetes Care 11(7).

131.

Dunnigan SK, Ebadi H, Breiner A, Katzberg HD, Lovblom LE, Perkins BA, Bril V. Conduction slowing in diabetic sensorimotor polyneuropathy. Diabetes Care. 2013;36(11):3684–90. https://doi.org/10.2337/dc13-0746.CrossRefPubMedPubMedCentral

132.

Gumy LF, Bampton ETW, Tolkovsky AM. Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol Cell Neurosci. 2008;37(2):298–311. https://doi.org/10.1016/j.mcn.2007.10.004.CrossRefPubMed

133.

Feldman EL, Nave K-A, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93(6):1296–313. https://doi.org/10.1016/j.neuron.2017.02.005.CrossRefPubMedPubMedCentral

134.

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.CrossRefPubMedPubMedCentral

135.

Padilla A, Descorbeth M, Almeyda AL, Payne K, De Leon M. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res. 2011;1370:64–79. https://doi.org/10.1016/j.brainres.2010.11.013.CrossRefPubMed

136.

Legrand-Poels S, Esser N, L’homme L, Scheen A, Paquot N, Piette J. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Alterat Metab Pathw Therap Targets. 2014;92(1):131–41. https://doi.org/10.1016/j.bcp.2014.08.013.CrossRef

137.

Zheng H, Sun W, Zhang Q, Zhang Y, Ji L, Liu X, Zhu X, Ye H, Xiong Q, Li Y, Lu B, Zhang S. Pro-inflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: a prospective cohort study. EClinicalMedicine. 2021;31: 100649. https://doi.org/10.1016/j.eclinm.2020.100649.CrossRefPubMed

138.

Hangping Z, Ling H, Ji L, Wenting Z, Xiaoxia L, Qi Z, Xiaoming Z, Qingchun L, Yiming L, Qian X, Hu J, Bin L, Shuo Z. The preventive effect of IL-1beta antagonist on diabetic peripheral neuropathy. Endocr, Metab Immune Disord Drug Targets. 2019. https://doi.org/10.2174/1871530319666191022114139.CrossRef

139.

Liu S, Zheng H, Zhu X, Mao F, Zhang S, Shi H, Li Y, Lu B. Neutrophil-to-lymphocyte ratio is associated with diabetic peripheral neuropathy in type 2 diabetes patients. Diabetes Res Clin Pract. 2017. https://doi.org/10.1016/j.diabres.2017.05.008.CrossRefPubMedPubMedCentral

140.

Frazier WA, Hogue Angeletti R, Bradshaw RA. Nerve growth factor and insulin. Science. 1972;176(4034):482–8. https://doi.org/10.1126/science.176.4034.482.CrossRefPubMed

141.

Toth C, Brussee V, Zochodne DW. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia. 2006;49(5):1081–8. https://doi.org/10.1007/s00125-006-0169-8.CrossRefPubMed

142.

Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes. 2004;53(7):1824–30. https://doi.org/10.2337/diabetes.53.7.1824.CrossRefPubMed

143.

Guo G, Kan M, Martinez JA, Zochodne DW. Local insulin and the rapid regrowth of diabetic epidermal axons. Neurobiol Dis. 2011;43(2):414–21. https://doi.org/10.1016/j.nbd.2011.04.012.CrossRefPubMed

144.

Singhal A, Cheng C, Sun H, Zochodne DW. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res. 1997;763(2):209–14. https://doi.org/10.1016/S0006-8993(97)00412-5.CrossRefPubMed

145.

Lupachyk S, Watcho P, Stavniichuk R, Shevalye H, Obrosova IG. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy. Diabetes. 2013;62(3):944–52. https://doi.org/10.2337/db12-0716.CrossRefPubMedPubMedCentral

146.

Roustit M, Loader J, Deusenbery C, Baltzis D, Veves A. Endothelial dysfunction as a link between cardiovascular risk factors and peripheral neuropathy in diabetes. J Clin Endocrinol Metab. 2016;101(9):3401–8. https://doi.org/10.1210/jc.2016-2030.CrossRefPubMedPubMedCentral

147.

Kim H, Kim JJ, Yoon Y. Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves. Endocr Metab Immune Disord Drug Targets. 2012. https://doi.org/10.2174/187153012800493486.CrossRefPubMedPubMedCentral

148.

Groop P-H, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab. 2005;1(2):100–10. https://doi.org/10.1038/ncpendmet0046.CrossRefPubMed

149.

Hsu P-C, Liao P-Y, Chang H-H, Chiang J, Huang Y-C, Lo L-C. Nailfold capillary abnormalities are associated with type 2 diabetes progression and correlated with peripheral neuropathy. Medicine. 2016;95: e5714. https://doi.org/10.1097/MD.0000000000005714.CrossRefPubMedPubMedCentral

150.

Rossor AM, Reilly MM. Blood biomarkers of peripheral neuropathy. Acta Neurol Scand. 2022;146(4):325–31. https://doi.org/10.1111/ane.13650.CrossRefPubMedPubMedCentral

151.

Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23(3):174–7. https://doi.org/10.1111/jns.12279.CrossRefPubMed

152.

van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, Barro C, van Schaik IN, Kuhle J, Eftimov F. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):187–94. https://doi.org/10.1111/jns.12319.CrossRefPubMed

153.

Hayashi T, Nukui T, Piao J-L, Sugimoto T, Anada R, Matsuda N, Yamamoto M, Konishi H, Dougu N, Nakatsuji Y. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain and Behavior. 2021;11(5): e02084. https://doi.org/10.1002/brb3.2084.CrossRefPubMedPubMedCentral

154.

Adki K, Kulkarni Y. Biomarkers in diabetic neuropathy. Arch Physiol Biochem. 2020;129:1–16. https://doi.org/10.1080/13813455.2020.1837183.CrossRef

155.

Baka P, Escolano-Lozano F, Birklein F. Systemic inflammatory biomarkers in painful diabetic neuropathy. J Diabetes Complicat. 2021;35(10): 108017. https://doi.org/10.1016/j.jdiacomp.2021.108017.CrossRef

156.

Sommer C, Kress M. Recent findings on how pro-inflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Festschrift Dedicated to Prof Manfred Zimmermann on the Occasion of His 70th Birthday, 2004;361(1): 184–187. https://doi.org/10.1016/j.neulet.2003.12.007.

157.

Sun JJ, Tang L, Zhao XP, Xu JM, Xiao Y, Li H. Infiltration of blood-derived macrophages contributes to the development of diabetic neuropathy. J Immunol Res. 2019;2019:7597382. https://doi.org/10.1155/2019/7597382.CrossRefPubMedPubMedCentral

158.

de Vries HE, Blom-Roosemalen MCM, van Oosten M, de Boer AG, van Berkel TJC, Breimer DD, Kuiper J. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37–43. https://doi.org/10.1016/0165-5728(95)00148-4.CrossRefPubMed

159.

Cunha T, Verri W, Silva J, Poole S, Cunha F, Ferreira S. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA. 2005;102:1755–60. https://doi.org/10.1073/pnas.0409225102.CrossRefPubMedPubMedCentral

160.

Conti G, Scarpini E, Baron P, Livraghi S, Tiriticco M, Bianchi R, Vedeler C, Scarlato G. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1β and p75NTR. J Neurol Sci. 2002;195:35–40. https://doi.org/10.1016/S0022-510X(01)00684-0.CrossRefPubMed

161.

Keswani SC, Polley M, Pardo CA, Griffin JW, McArthur JC, Hoke A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol. 2003;54(3):287–96. https://doi.org/10.1002/ana.10645.CrossRefPubMed

162.

Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, Koenig W, Heier M, Püttgen S, Thorand B, Peters A, Roden M, Meisinger C, Ziegler D. Pro-inflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study. Diabetes Care. 2017;40(4):569–76. https://doi.org/10.2337/dc16-2259.CrossRefPubMed

163.

Herder C, Dalmas E, Böni-Schnetzler M, Donath M. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab. 2015;26:551–63. https://doi.org/10.1016/j.tem.2015.08.001.CrossRefPubMed

164.

Herder C, Kannenberg JM, Carstensen-Kirberg M, Strom A, Bönhof GJ, Rathmann W, Huth C, Koenig W, Heier M, Krumsiek J, Peters A, Meisinger C, Roden M, Thorand B, Ziegler D. A systemic inflammatory signature reflecting cross talk between innate and adaptive immunity is associated with incident polyneuropathy: KORA F4/FF4 study. Diabetes. 2018;67(11):2434–42. https://doi.org/10.2337/db18-0060.CrossRefPubMed

165.

Jin HY, Park TS. Role of inflammatory biomarkers in diabetic peripheral neuropathy. J Diabetes Investig. 2018;9(5):1016–8. https://doi.org/10.1111/jdi.12794.CrossRefPubMedPubMedCentral

166.

Ascaso P, Palanca A, Martinez-Hervás S, Sanz MJ, Ascaso JF, Piqueras L, Real JT. Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Int J Clin Pract. 2021;75(8): e14302. https://doi.org/10.1111/ijcp.14302.CrossRefPubMed

167.

Okdahl T, Brock C, Fløyel T, Wegeberg A-ML, Jakobsen PE, Ejskjaer N, Pociot F, Brock B, Størling J. Increased levels of inflammatory factors are associated with severity of polyneuropathy in type 1 diabetes. Clin Endocrinol. 2020;93(4):419–28. https://doi.org/10.1111/cen.14261.CrossRef

168.

Drel VR, Lupachyk S, Shevalye H, Vareniuk I, Xu W, Zhang J, Delamere NA, Shahidullah M, Slusher B, Obrosova IG. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α. Endocrinology. 2010;151(6):2547–55. https://doi.org/10.1210/en.2009-1342.CrossRefPubMedPubMedCentral

169.

Sun Q, Yan B, Yang D, Guo J, Wang C, Zhang Q, Shi Y, Shi X, Tian G, Liang X. Serum adiponectin levels are positively associated with diabetic peripheral neuropathy in Chinese patients with type 2 diabetes. Front Endocrinol. 2020. https://doi.org/10.3389/fendo.2020.567959.CrossRef

170.

Rodríguez AJ, dos Nunes V, S., Mastronardi, C. A., Neeman, T., & Paz-Filho, G. J. Association between circulating adipocytokine concentrations and microvascular complications in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of controlled cross-sectional studies. J Diabetes Complicat. 2016;30(2):357–67. https://doi.org/10.1016/j.jdiacomp.2015.11.004.CrossRef

171.

Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects—(CURES-133). Clin Biochem. 2015;48(1):33–8. https://doi.org/10.1016/j.clinbiochem.2014.10.009.CrossRefPubMed

172.

Chen J, Li C, Liu W, Yan B, Hu X, Yang F. MiRNA-155 silencing reduces sciatic nerve injury in diabetic peripheral neuropathy. J Mol Endocrinol. 2019;63(3):227–38. https://doi.org/10.1530/JME-19-0067.CrossRefPubMed

173.

Stochelski M, Wilmanski T, Walters M, Burgess J. D3T acts as a pro-oxidant in a cell culture model of diabetes-induced peripheral neuropathy. Redox Biol. 2018;21: 101078. https://doi.org/10.1016/j.redox.2018.101078.CrossRefPubMedPubMedCentral

174.

Li J, Zhang H, Xie M, Yan L, Chen J, Wang H. NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes Care. 2013;36(11):3405–10. https://doi.org/10.2337/dc13-0590.CrossRefPubMedPubMedCentral

175.

Groener JB, Reismann P, Fleming T, Kalscheuer H, Lehnhoff D, Hamann A, Roser P, Bierhaus A. C332C genotype of glyoxalase 1 and its association with late diabetic complications. Exp Clin Endocrinol Diabetes. 2013;121(7):436–9. https://doi.org/10.1055/s-0033-1345124.CrossRefPubMed

176.

Jack MM, Ryals JM, Wright DE. Protection from diabetes-induced peripheral sensory neuropathy—a role for elevated glyoxalase I? Exp Neurol. 2012;234(1):62–9. https://doi.org/10.1016/j.expneurol.2011.12.015.CrossRefPubMed

177.

Darvish M, Hajilou F. Diagnostic biomarkers of diabetic neuropathy. J Clin Res Rep. 2023. https://doi.org/10.31579/2690-1919/291.CrossRef

178.

Kim S-H, Choi MK, Park NY, Hyun J-W, Lee MY, Kim HJ, Jung SK, Cha Y. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep. 2020;10(1):7995. https://doi.org/10.1038/s41598-020-64511-5.CrossRefPubMedPubMedCentral

179.

Maalmi H, Strom A, Petrera A, Hauck SM, Strassburger K, Kuss O, GDS Group. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia. 2023;66(3):579–89. https://doi.org/10.1007/s00125-022-05846-8.CrossRefPubMed

180.

Morgenstern J, Groener JB, Jende JME, Kurz FT, Strom A, Göpfert J, Kender Z, Le Marois M, Brune M, Kuner R, Herzig S, Roden M, Ziegler D, Bendszus M, Szendroedi J, Nawroth P, Kopf S, Fleming T. Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia. 2021;64(12):2843–55. https://doi.org/10.1007/s00125-021-05557-6.CrossRefPubMedPubMedCentral

181.

World Health Organisation. Programme on Traditional Medicine. General guidelines for methodologies on research and evaluation of traditional medicine. WHO/EDM/TRM/2000.1. WHO IRIS. 2000. https://apps.who.int/iris/handle/10665/66783.

182.

Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TPA. Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr. 2007;40(3):163–73. https://doi.org/10.3164/jcbn.40.163.CrossRefPubMedPubMedCentral

183.

Kennedy DO, Wightman EL. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr. 2011;2(1):32–50. https://doi.org/10.3945/an.110.000117.CrossRefPubMedPubMedCentral

184.

Jarald E, Balakrishnan S, Jain DC. Diabetes and herbal medicines. Iran J Pharmacol Ther. 2008;7(1):97–106.

185.

Akhtar N, Khan BA, Majid A, Khan HM, Mahmood T, Gulfishan, Saeed T. Pharmaceutical and biopharmaceutical evaluation of extracts from different plant parts of indigenous origin for their hypoglycemic responses in rabbits. Acta Pol Pharm. 2011;68(6):919–25.PubMed

186.

Ratan ZA, Haidere MF, Hong YH, Park SH, Lee J-O, Lee J, Cho JY. Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res. 2021;45(2):199–210. https://doi.org/10.1016/j.jgr.2020.02.004.CrossRefPubMed

187.

Kumari K, Augusti KT. Antidiabetic and antioxidant effects of S-methyl cysteine sulfoxide isolated from onions (Allium cepa Linn) as compared to standard drugs in alloxan diabetic rats. Indian J Exp Biol. 2002;40:1005–9.PubMed

188.

Lakshmi MS, Rani SK, Reddy UK. A review on diabetes mellitus and the herbal plants used for its treatment. Asian J Pharm Clin Res. 2012;5(4):15–21.

189.

Thomson M, Al-Amin ZM, Al-Qattan KK, Shaban LH, Ali M. Antidiabetic and hypolipidaemic properties of garlic (Allium sativum) in streptozotocin-induced diabetic rats. Int J Diabetes Metab. 2019;15(3):108–15. https://doi.org/10.1159/000497643.CrossRef

190.

Laha S, Paul S. Gymnema sylvestre (Gurmar): a potent herb with antidiabetic and antioxidant potential. Pharmacogn J. 2019;11(2):201–6.CrossRef

191.

Patil R, Patil R, Ahirwar B, Ahirwar D. Isolation and characterization of antidiabetic component (bioactivity—Guided fractionation) from Ocimum sanctum L (Lamiaceae) aerial part. Asian Pac J Trop Med. 2011;4(4):278–82. https://doi.org/10.1016/S1995-7645(11)60086-2.CrossRefPubMed

192.

Islam M. Antidiabetic potential of Ocimum sanctum Linn. Int J Adv Biochem Res. 2022;6:38–41. https://doi.org/10.33545/26174693.2022.v6.i2a.132.CrossRef

193.

Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10(1):24. https://doi.org/10.1186/1475-2891-10-24.CrossRefPubMedPubMedCentral

194.

Micheli L, Lucarini E, Trallori E, Avagliano C, De Caro C, Russo R, Calignano A, Ghelardini C, Pacini A, Di Cesare Mannelli L. Phaseolus vulgaris L. extract: alpha-amylase inhibition against metabolic syndrome in mice. Nutrients. 2019. https://doi.org/10.3390/nu11081778.CrossRefPubMedPubMedCentral

195.

Sheliya MA, Rayhana B, Ali A, Pillai KK, Aeri V, Sharma M, Mir SR. Inhibition of α-glucosidase by new prenylated flavonoids from euphorbia hirta L. herb. J Ethnopharmacol. 2015;176:1–8. https://doi.org/10.1016/j.jep.2015.10.018.CrossRefPubMed

196.

Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity. Food Chem. 2022;383: 132531. https://doi.org/10.1016/j.foodchem.2022.132531.CrossRefPubMed

197.

Al-Ishaq R, Abotaleb M, Kubatka P, Kajo K, Büsselberg D. Flavonoids and their antidiabetic effects: cellular mechanisms and effects to improve blood sugar levels. Biomolecules. 2019;9:430. https://doi.org/10.3390/biom9090430.CrossRefPubMedPubMedCentral

198.

Basu P, Basu A. In vitro and in vivo effects of flavonoids on peripheral neuropathic pain. Molecules. 2020. https://doi.org/10.3390/molecules25051171.CrossRefPubMedPubMedCentral

199.

Cao Y-L, Lin J-H, Hammes H-P, Zhang C. Flavonoids in treatment of chronic kidney disease. Molecules. 2022. https://doi.org/10.3390/molecules27072365.CrossRefPubMedPubMedCentral

200.

Caro-Ordieres T, Marín-Royo G, Opazo-Ríos L, Jiménez-Castilla L, Moreno JA, Gómez-Guerrero C, Egido J. The coming age of flavonoids in the treatment of diabetic complications. J Clin Med. 2020. https://doi.org/10.3390/jcm9020346.CrossRefPubMedPubMedCentral

201.

Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 2002;96(2):67–202. https://doi.org/10.1016/S0163-7258(02)00298-X.CrossRefPubMed

202.

Jasmin, Jaitak V. A review on molecular mechanism of flavonoids as antidiabetic agents. Mini-Rev Med Chem. 2018. https://doi.org/10.2174/1389557519666181227153428.CrossRef

203.

Oh YS. Bioactive compounds and their neuroprotective effects in diabetic complications. Nutrients. 2016;8:472.CrossRefPubMedPubMedCentral

204.

Sood A, Kumar B, Singh S, Prashar P, Gautam A, Gulati M, Pandey N, Melkani I, Awasthi A, Saraf S, Vidari G, Ozdemir M, Hussain F, Tariq-Anwer-Bayrakdar E, Sheet M, Gupta S, Porwal O. Flavonoids as potential therapeutic agents for the management of diabetic neuropathy. Curr Pharm Des. 2020. https://doi.org/10.2174/1381612826666200826164322.CrossRefPubMed

205.

Testa R, Bonfigli AR, Genovese S, De Nigris V, Ceriello A. The possible role of flavonoids in the prevention of diabetic complications. Nutrients. 2016. https://doi.org/10.3390/nu8050310.CrossRefPubMedPubMedCentral

206.

Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi Pharm J. 2017;25(2):149–64. https://doi.org/10.1016/j.jsps.2016.04.025.CrossRefPubMed

207.

Hosseinzadeh H, Nassiri-Asl M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest. 2014;37(9):783–8. https://doi.org/10.1007/s40618-014-0096-3.CrossRefPubMed

208.

Ghorbani A. Mechanisms of antidiabetic effects of flavonoid rutin. Biomed Pharmacother. 2017;96:305–12. https://doi.org/10.1016/j.biopha.2017.10.001.CrossRefPubMed

209.

Muvhulawa N, Dludla PV, Ziqubu K, Mthembu SXH, Mthiyane F, Nkambule BB, Mazibuko-Mbeje SE. Rutin ameliorates inflammation and improves metabolic function: a comprehensive analysis of scientific literature. Pharmacol Res. 2022;178: 106163. https://doi.org/10.1016/j.phrs.2022.106163.CrossRefPubMed

210.

Sattanathan K, C.K., D., R., U, Manavalan R. Beneficial health effects of rutin supplementation in patients with diabetes mellitus. J Appl Pharm Sci. 2011;1:227–31.

211.

Ansari P, Choudhury ST, Seidel V, Rahman AB, Aziz MdA, Richi AE, Rahman A, Jafrin UH, Hannan JMA, Abdel-Wahab YHA. Therapeutic potential of quercetin in the management of type-2 diabetes mellitus. Life. 2022. https://doi.org/10.3390/life12081146.CrossRefPubMedPubMedCentral

212.

Bule M, Abdurahman A, Nikfar S, Abdollahi M, Amini M. Antidiabetic effect of quercetin: a systematic review and meta-analysis of animal studies. Food Chem Toxicol. 2019;125:494–502. https://doi.org/10.1016/j.fct.2019.01.037.CrossRefPubMed

213.

Feng X, Bu F, Huang L, Xu W, Wang W, Wu Q. Preclinical evidence of the effect of quercetin on diabetic nephropathy: a meta-analysis of animal studies. Eur J Pharmacol. 2022;921: 174868. https://doi.org/10.1016/j.ejphar.2022.174868.CrossRefPubMed

214.

Haddad P, Eid H. The antidiabetic potential of quercetin: underlying mechanisms. Curr Med Chem. 2016. https://doi.org/10.2174/0929867323666160909153707.CrossRef

215.

Khursheed R, Singh SK, Wadhwa S, Gulati M, Awasthi A. Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems. Drug Discov Today. 2020;25(1):209–22. https://doi.org/10.1016/j.drudis.2019.11.001.CrossRefPubMed

216.

Okamoto T. Safety of quercetin for clinical application. Int J Mol Med. 2005;16:275–8. https://doi.org/10.3892/ijmm.16.2.275. (Review).CrossRefPubMed

217.

Rajesh U, Dhanaraj S. A critical review on quercetin bioflavonoid and its derivatives: scope, synthesis, and biological applications with future prospects. Arab J Chem. 2023;16(8): 104881. https://doi.org/10.1016/j.arabjc.2023.104881.CrossRef

218.

Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, Merghany RM, El Mahdy NM, Kılıç CS, Sytar O, Sharifi-Rad M, Sharopov F, Martins N, Martorell M, Cho WC. Therapeutic potential of quercetin: new insights and perspectives for human health. ACS Omega. 2020;5(20):11849–72. https://doi.org/10.1021/acsomega.0c01818.CrossRefPubMedPubMedCentral

219.

Septembre-Malaterre A, Boumendjel A, Seteyen A-LS, Boina C, Gasque P, Guiraud P, Sélambarom J. Focus on the high therapeutic potentials of quercetin and its derivatives. Phytomed Plus. 2022;2(1): 100220. https://doi.org/10.1016/j.phyplu.2022.100220.CrossRefPubMedPubMedCentral

220.

Zou H, Ye H, Kamaraj R, Zhang T, Zhang J, Pavek P. A review on pharmacological activities and synergistic effect of quercetin with small molecule agents. Phytomedicine. 2021;92: 153736. https://doi.org/10.1016/j.phymed.2021.153736.CrossRefPubMed

221.

Kamalakkannan N, Prince P. The influence of rutin on the extracellular matrix in streptozotocin-induced diabetic rat kidney. J Pharm Pharmacol. 2006;58:1091–8. https://doi.org/10.1211/jpp.58.8.0010.CrossRefPubMed

222.

Fernandes AAH, Novelli ELB, Okoshi K, Okoshi MP, Muzio BPD, Guimarães JFC, Júnior AF. Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomed Pharmacother Biomed Pharmacother. 2010;64(3):214–9.CrossRefPubMed

223.

Niture N, Ansari A, Naik S. Anti-hyperglycemic activity of Rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. Indian J Exp Biol. 2014;52:720–7.PubMed

224.

Hsu C-Y, Shih H-Y, Chia Y-C, Lee C-H, Ashida H, Lai Y-K, Weng C-F. Rutin potentiates insulin receptor kinase to enhance insulin-dependent glucose transporter 4 translocation. Mol Nutr Food Res. 2014;58(6):1168–76. https://doi.org/10.1002/mnfr.201300691.CrossRefPubMed

225.

Hao H, Shao Z, Tang D, Lu Q, Chen X, Yin X, Wu J, Chen H. Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. Life Sci. 2012;91:959–67. https://doi.org/10.1016/j.lfs.2012.09.003.CrossRefPubMed

226.

Diwan V, Brown L, Gobe GC. The flavonoid rutin improves kidney and heart structure and function in an adenine-induced rat model of chronic kidney disease. J Funct Foods. 2017;33:85–93. https://doi.org/10.1016/j.jff.2017.03.012.CrossRef

227.

Ganesan D, Albert A, Paul E, Ananthapadmanabhan K, Andiappan R, Sadasivam SG. Rutin ameliorates metabolic acidosis and fibrosis in alloxan induced diabetic nephropathy and cardiomyopathy in experimental rats. Mol Cell Biochem. 2020;471(1):41–50. https://doi.org/10.1007/s11010-020-03758-y.CrossRefPubMed

228.

Tian R, Yang W, Xue Q, Gao L, Huo J, Ren D, Chen X. Rutin ameliorates diabetic neuropathy by lowering plasma glucose and decreasing oxidative stress via Nrf2 signaling pathway in rats. Eur J Pharmacol. 2016;771:84–92. https://doi.org/10.1016/j.ejphar.2015.12.021.CrossRefPubMed

229.

Mittal R, Kumar A, Singh DP, Bishnoi M, Nag TC. Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: Targeting Nrf2/HO-1/NF-kB and COX signaling pathway. Inflammopharmacology. 2018;26(3):755–68. https://doi.org/10.1007/s10787-017-0413-5.CrossRefPubMed

230.

Yan L, Vaghari-Tabari M, Malakoti F, Moein S, Qujeq D, Yousefi B, Asemi Z. Quercetin: an effective polyphenol in alleviating diabetes and diabetic complications. Crit Rev Food Sci Nutr. 2022. https://doi.org/10.1080/10408398.2022.2067825.CrossRefPubMed

231.

Lai P-B, Zhang L, Yang L-Y. Quercetin ameliorates diabetic nephropathy by reducing the expressions of transforming growth factor-β1 and connective tissue growth factor in streptozotocin-induced diabetic rats. Ren Fail. 2012;34(1):83–7. https://doi.org/10.3109/0886022X.2011.623564.CrossRefPubMed

232.

Elbe H, Vardi N, Esrefoglu M, Ates B, Yologlu S, Taskapan C. Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol. 2015;34(1):100–13. https://doi.org/10.1177/0960327114531995.CrossRefPubMed

233.

Ding T, Wang S, Zhang X, Zai W, Fan J, Chen W, Bian Q, Luan J, Shen Y, Zhang Y, Ju D, Mei X. Kidney protection effects of dihydroquercetin on diabetic nephropathy through suppressing ROS and NLRP3 inflammasome. Phytomedicine. 2018;41:45–53. https://doi.org/10.1016/j.phymed.2018.01.026.CrossRefPubMed

234.

Du L, Chengcheng L, Xuan Q, Yibing C, Lei W, Hao Y, Xizhi L, Yuan L, Xiaoxing Y, Qian L. Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. Pharmacol Res. 2019;146: 104320. https://doi.org/10.1016/j.phrs.2019.104320.CrossRef

235.

Tang L, Li K, Zhang Y, Li H, Li A, Xu Y, Wei B. Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats. Sci Rep. 2020;10(1):2440. https://doi.org/10.1038/s41598-020-59411-7.CrossRefPubMedPubMedCentral

236.

Gao W, Zan Y, Wang Z, Hu X, Huang F. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKC-dependent activation of TRPV1. Acta Pharmacol Sin. 2016. https://doi.org/10.1038/aps.2016.58.CrossRefPubMedPubMedCentral

237.

Ji C, Xu Y, Han F, Sun D, Zhang H, Li X, Yao X, Wang H. Quercetin alleviates thermal and cold hyperalgesia in a rat neuropathic pain model by inhibiting Toll-like receptor signaling. Biomed Pharmacother. 2017;94:652–8. https://doi.org/10.1016/j.biopha.2017.07.145.CrossRefPubMed

238.

Muto N, Matsuoka Y, Arakawa K, Kurita M, Omiya H, Taniguchi A, Kaku R, Morimatsu H. Quercetin attenuates neuropathic pain in rats with spared nerve injury. Acta Med Okayama. 2018;72(5):457–65.PubMed

239.

Anjaneyulu M, Chopra K. Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1001–5. https://doi.org/10.1016/S0278-5846(03)00160-X.CrossRefPubMed

240.

Çivi S, Emmez G, Dere ÜA, Börcek AÖ, Emmez H. Effects of quercetin on chronic constriction nerve injury in an experimental rat model. Acta Neurochir. 2016;158(5):959–65. https://doi.org/10.1007/s00701-016-2761-0.CrossRefPubMed

241.

Ye G, Lin C, Zhang Y, Ma Z, Chen Y, Kong L, Yuan L, Ma T. Quercetin alleviates neuropathic pain in the rat CCI model by mediating AMPK/MAPK pathway. J Pain Res. 2021;14:1289–301. https://doi.org/10.2147/JPR.S298727.CrossRefPubMedPubMedCentral

242.

Zhao B, Zhang Q, Liang X, Xie J, Sun Q. Quercetin reduces inflammation in a rat model of diabetic peripheral neuropathy by regulating the TLR4/MyD88/NF-κB signaling pathway. Eur J Pharmacol. 2021;912: 174607. https://doi.org/10.1016/j.ejphar.2021.174607.CrossRefPubMed

243.

Xie J, Song W, Liang X, Zhang Q, Shi Y, Liu W, Shi X. Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. Biomed Pharmacother. 2020;127: 110147. https://doi.org/10.1016/j.biopha.2020.110147.CrossRefPubMed

244.

Chaturvedi S, Agrawal S, Garg A, Rastogi V. Potential of nanoencapsulated quercetin topical formulations in the management of diabetic foot ulcer. Rev Bras. 2023;33(3):484–501. https://doi.org/10.1007/s43450-022-00345-8.CrossRef

245.

Ostadmohammadi V, Milajerdi A, Ayati E, Kolahdooz F, Asemi Z. Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019;33(5):1330–40. https://doi.org/10.1002/ptr.6334.CrossRefPubMed

246.

Mazloom Z, Abdollahzadeh SM, Dabbaghmanesh MH, Rezaianzadeh A. The Effect of quercetin supplementation on oxidative stress, glycemic control, lipid profile, and insulin resistance in type 2 diabetes: a randomized clinical trial. J Health Sci Surveill Sys. 2014;2:8–14.

247.

Yao Z, Gu Y, Zhang Q, Liu L, Meng G, Wu H, Xia Y, Bao X, Shi H, Sun S, Wang X, Zhou M, Jia Q, Wu Y, Song K, Gao W, Guo C, Niu K. Estimated daily quercetin intake and association with the prevalence of type 2 diabetes mellitus in Chinese adults. Eur J Nutr. 2019;58(2):819–30. https://doi.org/10.1007/s00394-018-1713-2.CrossRefPubMed

248.

Hussain SA, Ahmed ZA, Mahwi TO, Aziz TA. Quercetin dampens postprandial hyperglycemia in type 2 diabetic patients challenged with carbohydrates load. Int J Diabetes Res. 2012;1(3):32–5.CrossRef

249.

Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial. Int J Prev Med. 2013;4(7):778.

250.

Van den Eynde MDG, Geleijnse JM, Scheijen JLJM, Hanssen NMJ, Dower JI, Afman LA, Stehouwer CDA, Hollman PCH, Schalkwijk CG. Quercetin, but not epicatechin, decreases plasma concentrations of methylglyoxal in adults in a randomized, double-blind, placebo-controlled, crossover trial with pure flavonoids. J Nutr. 2018;148(12):1911–6. https://doi.org/10.1093/jn/nxy236.CrossRefPubMed

Title: Biomarkers and signaling pathways of diabetic nephropathy and peripheral neuropathy: possible therapeutic intervention of rutin and quercetin
Authors: Tamsheel Fatima Roohi
Seema Mehdi
Sadaf Aarfi
K. L. Krishna
Suman Pathak
Seikh Mohammad Suhail
Syed Faizan
Publication date: 19-12-2023
Publisher: Springer Nature Singapore
Keywords: Diabetic Retinopathy
Diabetic Retinopathy
Diabetic Nephropathy
Biomarkers
Published in: Diabetology International / Issue 2/2024
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-023-00680-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Rapid improvement of severe fatty liver in a patient with fulminant type 1 diabetes

Mortality in childhood-onset type 1 diabetes mellitus with onset between 1959 and 1996: A population-based study in Hokkaido, Japan

Gender differential in the pattern and severity of perceived symptoms among diabetes patients in India

Impacts of “Diabetes Theater,” a participative educational workshop for health care professionals, on participants: a patient empowerment perspective

Associations of ALT/AST, a marker of hepatosteatosis, with pulse rate in young women and with blood pressure in middle-aged women independently of abdominal fat accumulation and insulin resistance

Association between glycemic control and patient-reported outcomes in adults with type 1 diabetes in Japan: the SAGE study subanalysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials